CURE.X — Biocure Technology Income Statement
0.000.00%
Last trade - 00:00- CA$0.71m
- CA$0.72m
Annual income statement for Biocure Technology, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.86 | 0.408 | 0.674 | 0.353 | 0.103 |
| Operating Profit | -1.86 | -0.408 | -0.674 | -0.353 | -0.103 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.87 | -0.403 | -1.49 | -0.262 | -0.103 |
| Net Income After Taxes | -1.87 | -0.403 | -1.49 | -0.262 | -0.103 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -1.13 | -1.45 | -1.81 | -0.262 | -0.103 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.13 | -1.45 | -1.81 | -0.262 | -0.103 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.162 | -0.053 | -0.113 | -0.025 | -0.006 |